ArticleBMC oral health2025
Lipid metabolites as biomarkers and therapeutic targets in oral squamous cell carcinoma.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Experimental Models and Nanotechnology-Based Platforms in Oral Squamous Cell Carcinoma: From Tumor Biology to Translational Applications.Pharmaceutics · 2026Review
- Identification and Validation of a Lipid Metabolism-Related Gene Signature for Predicting Prognosis and Immunotherapy Response in Oral Squamous Cell Carcinoma.Metabolites · 2026Article
- Integrative Bulk and Single-Cell Transcriptomic Analysis Identifies a Hypoxia- and Lipid Metabolism-Related Prognostic Signature in Oral Squamous Cell Carcinoma: A Retrospective Study.International journal of molecular sciences · 2026Article
- Molecular Mechanisms in Oral Squamous Cell Carcinoma: Integrative Roles of Cancer-Associated Fibroblasts, Immune Microenvironment, and Precision Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Serum lipid profile patterns in patients with oral cancer and oral potentially malignant disorders.Bioinformation · 2026Article
- Lipid Metabolism and Oncogenesis.Cancer treatment and research · 2026Review
- Filtration-enriched metabolites and their association with salivary microbiota: a combined two-cohort analysis.Journal of oral microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
This study explores the association of lipid metabolism disruption and Oral Squamous Cell Carcinoma (OSCC). We aim to identify specific lipid biomarkers and therapeutic targets for OSCC. We included 78 OSCC patients and 80 healthy controls, and applied non-target lipidomics and transcriptomics for comprehensive analysis. Using ultra-high-performance liquid chromatography quadrupole-Orbitrap high-resolution accurate mass spectrometry (UHPLC/Q-Orbitrap HRMS) coupled with machine learning for diagnostic modeling, we identified potential lipid biomarkers. Transcriptomic analysis helped in pinpointing genetic and metabolic targets relevant to lipid metabolism in OSCC. Notably, we observed 70 differential lipid metabolites in the OSCC group, with nine achieving an AUC > 0.95, suggesting high potential as biomarkers. A diagnostic model based on 10 differentiated lipids yielded accuracy rates of 98.2% in a training cohort and 95.7% in a validation cohort. Additionally, the overexpression of DGKG, linked to poor prognosis, was noted to enhance migration and invasion of OSCC cells, marking it a potential target for therapy. This research underscores the critical role of lipid metabolic alterations in OSCC and highlights innovative diagnostic and therapeutic avenues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.